A Metal-Peptide Framework as a Nanozyme for the Attenuation of Amyloid-β Aggregation and Reactive Oxygen Species
Open Access
- 28 August 2025
- journal article
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (9) , 4346-4360
Abstract
Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by abnormal performance in memory, cognition, and language, and it imposes a heavy economic burden worldwide. Amyloidosis and oxidative stress are highly associated with AD progression, yet limited clinical drugs are available at present. Nanozymes exhibit diverse enzyme-mimetic activities and have attracted widespread attention as a promising alternative candidate for scavenging reactive oxygen species to maintain the oxidation–antioxidation balance in cells. Neurotoxic amyloid-β (Aβ) aggregation is also a critical event in AD pathology. The development of dual-targeting nanomaterials with antiamyloidosis ability and enzyme-mimicking activity is expected to be a promising strategy for the treatment of amyloidosis and reactive oxygen species-mediated AD progression. Here, bimetallic-peptide framework nanozymes (CuZn-PEP NZs) with amyloid-β (Aβ) attenuating ability, multiple enzyme-mimicking properties, and broad-spectrum reactive oxygen species scavenging capacity were endowed to inhibit Aβ fibrillization, disaggregate Aβ fibrils, and scavenge Aβ fibril-induced reactive oxygen species. An obvious inhibitory effect on Aβ fibrillization and a disaggregation effect on Aβ fibrils were observed after treatment with CuZn-PEP NZs. Meanwhile, the cytotoxicity of Aβ fibrils toward PC12 cells was significantly reduced by CuZn-PEP NZs. Meanwhile, CuZn-PEP NZs with multiple redox pairs exhibit superoxide dismutase, catalase, and glutathione peroxidase-mimicking enzyme properties simultaneously, which further display cytoprotective effects against Aβ fibril-induced reactive oxygen species and mitochondrial damage. Besides, cellular studies verified that CuZn-PEP NZs possess excellent biocompatibility and blood–brain barrier penetration capacity. Overall, these bimetallic-peptide framework nanozymes represent a promising perspective for attenuation of amyloid-β aggregation and reactive oxygen species simultaneously, which highlights the potential of nanozymes for the treatment of amyloidosis and reactive oxygen species-mediated AD progression.Keywords
Funding Information
- Shanghai Hongkou District Public Health Key Support Discipline Construction Project (HKGWFC202401)
- Shanghai Hongkou District Science and Technology Commission (2022-31)
This publication has 60 references indexed in Scilit:
- The Role of Reactive Oxygen Species in Alzheimer's Disease: From Mechanism to Biomaterials TherapyAdvanced Healthcare Materials, 2024
- Co‐Assembled Nanoparticles toward Multi‐Target Combinational Therapy of Alzheimer's Disease by Making Full Use of Molecular Recognition and Self‐AssemblyAdvanced Materials, 2024
- Multienzyme‐Like Nanozymes: Regulation, Rational Design, and ApplicationAdvanced Materials, 2023
- Peptide‐Functionalized Prussian Blue Nanomaterial for Antioxidant Stress and NIR Photothermal Therapy against Alzheimer's DiseaseSmall, 2023
- Crystalline Metal‐Peptide Networks: Structures, Applications, and Future OutlookChemBioChem, 2022
- ROS-triggered cycle amplification effect: A prodrug activation nanoamplifier for tumor-specific therapyActa Biomaterialia, 2022
- Cu2+‐Chelatable and ROS‐Scavenging MXenzyme as NIR‐II‐Triggered Blood–Brain Barrier‐Crossing Nanocatalyst against Alzheimer's DiseaseSmall, 2022
- An Organic Nanotherapeutic Agent Self‐Assembled from Cyanine and Cu (II) for Combined Photothermal and Chemodynamic TherapyAdvanced Healthcare Materials, 2021
- Construction of a bioinspired laccase-mimicking nanozyme for the degradation and detection of phenolic pollutantsApplied Catalysis B: Environment and Energy, 2019
- Guest‐Adaptable and Water‐Stable Peptide‐Based Porous Materials by Imidazolate Side Chain ControlAngewandte Chemie International Edition, 2013